Business

Ozempic Maker Novo Nordisk’s Investors AreNervously Looking Into the Future

Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.

This story summarizes reporting from The New York Times. Read the original for full context. Wire items stay in our news sitemap for seven days. Editorial policy.

Read full story on The New York Times →

Eshe Nelson1 Sept 2026, 02:06 pmUpdated 3h ago1 min readBusinessGlobal

Global — Eshe Nelson

Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future

Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.

This report is published with credit to The New York Times. The wire sent a summary; open the original for any extra context. Read on The New York Times →

Source: The New York Times · Eshe Nelson. Published 1 Sept 2026, 02:06 pm.

Next news → At G20 Summit, Scott Bessent Says U.S. Has…Browse more stories